JC17 Rec'd PCT/PTO 04 MAI 2001

FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR
PF86PCTSEQ	09/831061

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/FR99/02734	08 NOV 1999 (08.11.99)	06 NOV 1998 (06.11.98)

TITLE OF INVENTION

USE OF ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS

APPLICANT(S) FOR DO/EO/US

BONNEFOY, Jean-Yves; LECOANET, Sybille; AUBRY, Jean-Pierre; JEANNIN, Pascale; BAUSSANT, Thierry

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☒ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.
8. ☒ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/831061	PCT/FR99/02734	PF86PCTSEQ

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	**$1000.00**
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	**$860.00**
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	**$710.00**
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	**$690.00**
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	**$100.00**
	ENTER APPROPRIATE BASIC FEE AMOUNT =	**$860.00**
	Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	**$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	24 - 20 =	4	x $18.00	**$72.00**
Independent claims	3 - 3 =	0	x $80.00	**$0.00**
Multiple Dependent Claims **(check if applicable).**			☐	**$0.00**
	TOTAL OF ABOVE CALCULATIONS =			**$932.00**
☐	Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.			**$0.00**
	SUBTOTAL =			**$932.00**
	Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +			**$0.00**
	TOTAL NATIONAL FEE =			**$932.00**
☐	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).**			**$0.00**
	TOTAL FEES ENCLOSED =			**$932.00**
			Amount to be: refunded	$
			charged	$

a. ☒ A check in the amount of **$932.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **8-3220** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

G. Patrick Sage
THE FIRM OF HUESCHEN AND SAGE
500 Columbia Plaza
350 East Michigan Ave.
Kalamazoo, MI 49007

G. PATRICK SAGE
SIGNATURE

G. PATRICK SAGE
NAME

37,710
REGISTRATION NUMBER

May 4, 2001
DATE

09/831061
JC18 Rec'd PCT/PTO 04 MAY 2001
PF86PCTSEQ/dlh

* * * * *

Applicant : Jean-Yves BONNEOY, Sybille LECOANET, Jean-Pierre AUBRY, Pascale JEANNIN, and Thierry BAUSSANT

Filed : May 4, 2001

Title : USE OF ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS

* * * * *

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

A soon as a Serial Number and Filing Date have been accorded the above-identified national phase application, kindly amend as follows:

IN THE CLAIMS: Kindly cancel all of the claims, 1 through 24, and replace by Claims 25 through 48 as provided herewith.

IN THE ABSTRACT: Herewith please find an Abstract of the Disclosure in U.S. format.

REMARKS

The present application is a national phase filing of PCT/FR99/02734.

Applicants have cancelled all of the originally-filed Claims, 1 through 24. New Claims, 25 through 48, have been added to better encompass the full scope and breadth of the invention notwithstanding Applicants belief that the Claims would

have been allowable as originally filed. Accordingly, Applicants assert that no Claims have been narrowed within the meaning of Festo.

A U.S. format Abstract is provided.

Entry of the new Claims and Abstract and early and favorable action on the merits of this application are respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By: G. Patrick Sage
G. PATRICK SAGE

Dated: May 3, 2001
Customer No.: 25,666
500 Columbia Plaza
350 East Michigan Ave.
Kalamazoo, MI 49007
(616) 382-0030

Enclosure: Postal Card Receipt
Claims 25 through 48
Abstract of the Disclosure

ABSTRACT OF THE DISCLOSURE

The invention concerns the use of an enterobacterium protein OmpA, preferably Klebsiella *pneumoniae* P40 protein, for specific targeting of a biologically active substance associated therewith towards antigen-presenting cells, in particular human dendritic cells. The invention also concerns the sue of the OmpA protein for preparing a pharmaceutical composition for preventing and/or treating diseases, in particular cancers related to a tumor-associated antigen, autoimmune diseases or infectious diseases.

BEST AVAILABLE COPY

CLAIMS

25. A process of using an enterobacterium OmpA protein, or a fragment thereof, for preparing a composition intended for specific targeting of a biologically active substance, which is associated with it, to antigen-presenting cells, wherein said enterobacterium OmpA protein, or a fragment thereof, is internalized into the antigen-presenting cells.

26. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, binds specifically to antigen-presenting cells.

27. The process of claim 25, wherein said antigen-presenting cells are chosen from dendritic cells, monocytes and B lymphocytes.

28. The process of claim 27, wherein said antigen-presenting cells are dendritic cells.

29. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, is obtained from a culture of said enterobacterium, using an extraction process.

30. The process of claim 25, wherein said enterobacterium OmpA protein, or a fragment thereof, is obtained by a recombinant process.

31. The process of claim 25, wherein said enterobacterium is Klebsiella *pneumoniae*.

32. The process of claim 31, wherein the amino acid sequence of said OmpA protein, or a fragment thereof, comprises:

a) the amino acid sequence having sequence SEQ ID No 2;

b) the amino acid sequence of a sequence having at least 80% homology with the sequence SEQ ID No 2; or

c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).

09831504.080401

33. The process of claim 25, wherein said biologically active substance is chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.

34. The process of claim 33, wherein said biologically active substance is coupled by covalent attachment with said OmpA protein, or a fragment thereof.

35. The process of claim 34, wherein the coupling by covalent attachment is chemical coupling.

36. The process of claim 35, wherein one or more attachment elements are introduced into said OmpA protein, or a fragment thereof, and/or into said biologically active substance, in order to facilitate the chemical coupling.

37. The process of claim 36, wherein said attachment element introduced is an amino acid.

38. The process of claim 34, wherein said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

39. The process of claim 38, wherein said biologically active substance is an antigen or a hapten.

40. A method for modifying the immune response to an antigen or a hapten with a composition intended for specific targeting of a biologically active substance, which is associated with it, to antigen-presenting cells, wherein an enterobacterium OmpA protein, or a fragment thereof, is internalized into the antigen-presenting cells.

41. The method of claim 40 for improving the immune response to an antigen or a hapten.

42. The method of claim 40 for preventing or treating a disease.

43. The method of claim 42, for preventing or treating a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by dendritic cells.

44. The method of claim 43, for preventing or treating cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections, cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.

45. The method of claim 44, for preventing or treating an infectious disease or a cancer associated with a tumor antigen.

46. A pharmaceutical composition effective in the method of claim 42 which comprises an adjuvant of immunity.

47. The pharmaceutical composition of claim 46 which is vehicled in a form which makes it possible to improve the stability and/or immunogenicity thereof.

48. The pharmaceutical composition of claim 46 which is vehicled in the form of a liposome, of a viral vector, or of a transformed host cell capable of expressing a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

4/PRTS

09/831061
JC18 Rec'd PCT/PTO 04 MAY 2001

USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR SPECIFIC TARGETING TO ANTIGEN-PRESENTING CELLS

The invention relates to the use of an enterobacterium OmpA protein, preferably the Klebsiella *pneumoniae* P40 protein, for specific targeting of a biologically active substance which is associated with it to antigen-presenting cells, in particular human dendritic cells. The invention also relates to the use of the OmpA protein for preparing a pharmaceutical composition intended for the prevention and/or treatment of diseases, in particular cancers associated with a tumor antigen, autoimmune diseases or infectious diseases.

Vaccination is an effective means of preventing or attenuating viral or bacterial infections. The success of vaccination campaigns in this domain has made it possible to extend the vaccine concept to other domains, such as that of cancer and of autoimmune diseases. With regard, for example, to certain forms of cancer, the ineffectiveness of conventional therapies and/or their side effects, such as chemotherapy or radiotherapy, has prompted the search for alternative therapy. Thus, specific tumor antigens expressed at the surface of tumor cells can be used as a target in immunotherapy for the elimination of these cells. One of the major problems commonly encountered in preparing these vaccines is that the vaccine antigens, when they are administered alone to the host, are not immunogenic enough to induce an immune response which is sufficiently effective to confer the desired protection. These antigens are thus often covalently coupled to a carrier molecule such as, for example, an epitope of the diphtheria toxin, the tetanus anatoxin (TT), a surface antigen of the hepatitis B virus, the VP1 antigen of the poliomyelitis virus or any other toxin, or viral or bacterial antigen, such as antigenic proteins derived from the enterobacterium external

membrane, which have the property of potentiating the immune response (humoral or cellular) of the antigen which is associated with it, for instance the OmpA protein named P40 derived from Klebsiella *pneumoniae* (described in international patent applications WO 95/27787 and WO 96/14415). However, in most cases, another component has proved to be necessary in order to increase the effectiveness of the vaccine and, currently, the only adjuvant authorized in humans is alum.

Through immunology, it has recently been discovered that dentritic cells (DCs) play a major role in the immune system. These cells, derived from bone marrow stem cells, are professional antigen-presenting cells involved in the antigen-specific primary immune response (Peters J. et al., 1996). They ingest or internalize antigens and present the fragments of these antigens to naïve T cells. This ingestion induces, at the surface of the dendritic cells, the expression of costimulation molecules such as CD80 and CD86. These molecules allow close interaction with T cells (Girolomoni G. and Ricciardi-Castagnoli P., 1997, Immunol. Today, 18, 102-104). Dendritic cells are distributed diffusely in tissues. They are found in the skin and lymphoid organs (Hinrich J. et al., 1996, Immunol. Today, 17, 273-277).

Due to their effectiveness in presenting antigens and in stimulating the immune system, dendritic cells have been used to generate antiviral (Ludewig B. et al., 1998, J. Virol., 72, 3812-3818; Brossard P. et al., 1997, J. Immunol., 158, 3270-3276) or anticancer (Nestle F.O. et al., 1998, Nat. Med., 4, 328-332) cytotoxic CTL responses. Approaches have consisted in loading dendritic cells *ex vivo* with the antigen of interest (peptides or cell lysate) and reimplanting these cells in the patient. Other approaches consist in transfecting dendritic cells *ex vivo* with the gene encoding the antigen of interest and in reinjecting these transfected cells (Gilboa E. et

al., 1998, Cancer Immunol. Immunother., 46, 82-87). These approaches have been used successfully in mice and recently in humans (Hsu F.J. et al., 1996, Nat. Med., 2, 52-58). Dendritic cells loaded with antigens present the peptides via class I or II molecules, and induce the activation of CD4 or CD8+ T lymphocytes. Consequently, the possibility of directing the antigens chosen, such as proteins or polysaccharides, or viral vectors capable of transferring genes encoding these antigens, toward dendritic cells would make it possible to improve the effectiveness of immune system stimulation. In addition, specific targeting of antigen-presenting cells (APCs), in particular dendritic cells, would make it possible to avoid the steps of removal, of purification and of *ex vivo* treatment of autologous or heterologous APCs with the tumor antigens or the viral vectors, and the reimplantation of the treated APCs.

In order to specifically target dendritic cells with active substances of interest, such as proteins or viral vectors capable of transferring genes encoding these proteins of interest, many studies have consisted in identifying molecules which would bind preferentially to the dendritic cells, or receptors which would be expressed specifically on the dendritic cells. A receptor DEC 205, involved in the treatment of the antigen, has been identified on murine (Jiang W. et al., 1995, Nature, 375, 151-155) and human (Kato M. et al., 1998, Immunogenetics, 47, 442-450) dendritic cells. The analysis of the structure of this receptor reveals carbohydrate-recognition domains which are thought to be involved in the capture, internalization and/or presentation of antigens carrying carbohydrate residues. However, the authors give no information concerning the ligands which can be bound by this receptor. On the other hand, the authors mention that the carbohydrate-recognition domains of the receptor DEC-205 which are thought to be involved in the capture, internalization and/or presentation of

antigens (cysteine-rich domains) are also present in more than 50 proteins, including some cell receptors.

Thus, there exists, today, a need for a compound which is capable of specifically targeting an antigen-presenting cell (APC), in particular a dendritic cell, and which is also capable of being internalized by said cell. Such a compound capable of binding specifically to these cells, and then of being internalized, would have the advantage of being able to be used as a compound for the transport and targeting of a biologically active substance, the effectiveness of which is modified by and/or linked to the binding and/or the internalization of this substance by these cells. In addition, it would be advantageous if this compound being sought could be easily associated with the active substance by chemical coupling or by coupling resulting from genetic fusion, or if it could be expressed at the surface of a host cell or at the surface of a viral particle for the transfer of a gene of interest into these APCs.

The authors of the present invention have demonstrated, surprisingly, that an enterobacterium external membrane protein of OmpA type, in particular the Klebsiella *pneumoniae* P40 protein, is capable not only of binding specifically to an APC, but also capable of being internalized by said APC, in particular by a dendritic cell.

Thus, the present invention relates to the use of an enterobacterium OmpA protein, or of a fragment thereof, for specific targeting of a biologically active substance which is associated with it to antigen-presenting cells.

In the present invention, the expression "antigen-presenting cells" will be intended to refer to professional APCs which form an integral part of the immune system, such as dendritic cells, macrophages, B lymphocytes or monocytes.

In the present invention, the term "protein" will also be intended to refer to peptides or

EP 0 963 206 B1

polypeptides, and the term "OmpA" (for "Outer Membrane Protein") will be intended to refer to external membrane proteins of type A.

The expression "fragment of an OmpA protein" is intended to refer to any fragment of amino acid sequence included in the amino acid sequence of the OmpA protein capable of binding specifically to APCs, in particular dendritic cells, and comprising at least 5 amino acids, preferably 10 amino acids, or more preferably 15 amino acids, said fragments also being capable of being internalized into said APCs.

The expression "biologically active substance" is intended to refer to any compound which is capable of exercising therapeutic activity and the activity of which can be modified via APCs. Mention may be made, as an example of such biologically active substances, but without being limited thereto, of immunogenic compounds such as antigens or haptens which are protein, poly- or oligosaccharide, glycoprotein or lipoprotein in nature, or in general of organic origin, these immunogenic compounds possibly being carried by complex structures such as bacteria or viral particles.

The expression "biologically active substance" is also intended to refer to any compound capable of modifying the functional activity of APCs, in particular the growth, differentiation or system of expression thereof. Mention may be made, as an example of such biologically active substances, but without being limited thereto, of cellular growth factors including cytokines (IL-4, IL-3, GM-CSF, TNF-α), and nucleic acids which encode homologous or heterologous proteins of interest and which are capable of being expressed by APCs.

A subject of the invention is also the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, binds specifically to antigen-presenting cells, and in that said enterobacterium OmpA protein,

or a fragment thereof, is internalized into the antigen-presenting cells.

Preferably, the invention comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said antigen-presenting cells are chosen from dendritic cells, monocytes and B lymphocytes, more preferably dendritic cells.

In a particular embodiment, the invention comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained from a culture of said enterobacterium, using an extraction process.

Processes for extraction of bacterial membrane proteins are known to those skilled in the art and will not be developed in the present description. Mention may be made, for example, but without being limited thereto, of the extraction process described by Hauew J.H. et al. (Eur. J. Biochem, 255, 446-454, 1998).

In another preferred embodiment, the invention also comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained by recombinant process.

Methods for preparing recombinant proteins are today well known to those skilled in the art and will not be developed in the present description; reference may, however, be made to the method described in the examples. Among the cells which can be used for producing these recombinant proteins, it is of course necessary to mention bacterial cells (Olins P.O. and Lee S.C., 1993, Recent advances in heterologous gene expression in E. coli. Curr. Op. Biotechnology 4:520-525), but also yeast cells (Buckholz R.G., 1993, Yeast Systems for the Expression of Heterologous Gene

Products. Curr. Op. Biotechnology 4:538-542), as well as animal cells, in particular cultures of mammalian cells (Edwards C.P. and Aruffo A., 1993, Current applications of COS cell based transient expression systems. Curr. Op. Biotechnology 4:558-563), and also insect cells in which it is possible to use processes implementing baculoviruses for example (Luckow V.A., 1993, Baculovirus systems for the expression of human gene products. Curr. Op. Biotechnology 4:564-572).

Most preferably, the use according to the invention is characterized in that said enterobacterium is Klebsiella *pneumoniae*.

In particular, the invention relates to the use according to the invention, characterized in that the amino acid sequence of said Klebsiella *pneumoniae* OmpA protein, or a fragment thereof, comprises:

a) the amino acid sequence having the sequence SEQ ID No 2;

b) the amino acid sequence of a sequence having at least 80%, preferably at least 85%, 90% or 95%, homology with the sequence SEQ ID No 2; or

c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).

The expression "sequence having at least 80%, preferably at least 85%, 90% or 95%, homology with the reference sequence SEQ ID No 2" is intended to refer to an amino acid sequence having a degree of identity, after optimal alignment, of at least 80%, 85%, 90% or 95%, respectively, with the reference sequence SEQ ID No 2, said homologous sequence, or a said fragment thereof of at least 5 amino acids as defined above in c), being characterized in that it binds specifically to antigen-presenting cells and, where appropriate, in that it is internalized into the antigen-presenting cells.

For the purpose of the invention, the expression "percentage of identity" between two nucleic acid or amino acid sequences is intended to refer to a percentage of nucleotides or of amino acid residues

which are identical between the two sequences to be compared, obtained after the best alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly and throughout their length. The best alignment or optimal alignment is the alignment for which the percentage of identity between the two sequences to be compared, as calculated hereinafter, is highest. Sequence comparisons between two nucleic acid or amino acid sequences are conventionally carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison", so as to identify and compare local regions of sequence similarity. The optimal alignment of the sequences for comparison can be produced, other than manually, by means of the local homology algorithm of Smith and Waterman (1981) [Ad. App. Math. 2:482], by means of the local homology algorithm of Neddleman and Wunsch (1970) [J. Mol. Biol. 48:443], by means of the similarity search method of Pearson and Lipman (1988) [Proc. Natl. Acad. Sci. USA 85:2444], by means of computer software using these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI, or BLASTN or BLASTX, Altschul et al., J. Mol. Biol. 215, 403, 1990).

The percentage of identity between two nucleic acid or amino acid sequences is determined by comparing these two optimally aligned sequences by window of comparison in which the region of the nucleic acid or amino acid sequence to be compared can comprise additions or deletions with respect to the reference sequence for optimal alignment between these two sequences. The percentage of identity is calculated by determining the number of identical positions for which the nucleotide or amino acid residue is identical between the two sequences, dividing this number of identical positions by the total number of positions in the window of comparison, and multiplying the result

obtained by 100 so as to obtain the percentage of identity between these two sequences.

The invention also comprises the use according to the invention, characterized in that said biologically active substance is chosen from proteins or peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.

A subject of the present invention is also the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said biologically active substance is coupled by covalent attachment with said OmpA protein, or a fragment thereof, in particular by chemical coupling.

In a particular embodiment, the use according to the invention is characterized in that one or more attachment elements is (are) introduced into said OmpA protein, or a fragment thereof, and/or into said biologically active substance, in order to facilitate the chemical coupling; preferably said attachment element introduced is an amino acid.

According to the invention, it is possible to introduce one or more attachment elements, in particular amino acids, in order to facilitate the coupling reactions between the OmpA protein, or a fragment thereof, and the biologically active substance, such as an antigen or a hapten. The covalent coupling between the OmpA protein, or a fragment thereof, and the biologically active substance, such as an antigen or a hapten, according to the invention can be carried out at the N- or C-terminal end of the OmpA protein, or a fragment thereof. The bifunctional reagents which allow this coupling will be determined as a function of the end of the OmpA protein, or a fragment thereof, chosen to perform the coupling, and on the nature of the biologically active substance to be coupled.

In another particular embodiment, the use according to the invention is characterized in that said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

The conjugates derived from coupling to said OmpA protein, or a fragment thereof, can be prepared by genetic recombination. The chimeric or hybrid protein (conjugate) can be produced using recombinant DNA techniques, by insertion into or addition to the DNA sequence encoding said OmpA protein, or a fragment thereof, of a sequence encoding said biologically active substance which is protein in nature.

The processes for synthesizing the hybrid molecules encompass the methods used in genetic engineering for constructing hybrid polynucleotides encoding the desired polypeptide sequences. Reference may, for example, be advantageously made to the technique for obtaining genes encoding fusion proteins, described by D.V. Goeddel (Gene expression technology, Methods in Enzymology, vol. 185, 3-187, 1990).

The invention relates most particularly to the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, characterized in that said biologically active substance is an antigen or a hapten.

In another aspect, the invention relates to the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, for modifying the immune response against an antigen or a hapten, preferably for improving the immune response against an antigen or a hapten.

The invention also comprises the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, for preparing a pharmaceutical composition intended to prevent or to

treat a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by antigen-presenting cells, preferably by dendritic cells.

Preferably, the use according to the invention is related to the preparation of a pharmaceutical composition intended to prevent or to treat cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections, cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.

A subject of the invention is in particular the use of an enterobacterium OmpA protein, or of a fragment thereof, according to the invention, for preparing a pharmaceutical vaccine composition intended to prevent or to treat an infectious disease or a cancer associated with a tumor antigen.

The invention also comprises the use according to the invention, characterized in that said pharmaceutical composition also comprises an adjuvant which promotes the immune response, such as alum.

The invention also comprises the use according to the invention, characterized in that said pharmaceutical composition is vehicled in a form which makes it possible to improve the stability and/or the immunogenicity thereof, in particular in the form of a liposome, of a viral vector or of a transformed host cell capable of expressing a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

The legends of the figures and examples which follow are intended to illustrate the invention without in any way limiting the scope thereof.

Legends of the figures:

Figure 1: Binding of rP40-Alexa to various cell types. After incubation of rP40-Alexa on various cell types, the specific binding of rP40-Alexa (bold line) is

measured by flow cytometry. The binding of a nonrelevant protein (glycophorin) is represented with a fine line.

Figure 2: Influence of the concentration of rP40 on the binding to dendritic cells.

Figure 3: Inhibition of the binding of rP40-Alexa to dendritic cells, with unlabeled rP40.

After incubation of dendritic cells with various concentrations of unlabeled rP40, rP40-Alexa is added. The binding of rP40-Alexa is quantified by flow cytometry.

Figure 4: Evaluation of the binding of various labeled proteins to dendritic cells.

P40, TT (tetanus anatoxin) and BB (derived from the streptococcus G protein) carrier proteins labeled with Alexa are incubated with dendritic cells (thick line). A nonrelevant protein is used as a negative control (fine line). The binding is measured by flow cytometry.

Figure 5A and 5B: Internalization of rP40-Alexa into dendritic cells.

After incubation of dendritic cells with rP40-Alexa at 4°C (left-hand panel, figure 5A) or at 37°C (right-hand panel, figure 5B), the cells are observed by confocal microscopy (x 220 magnification).

Example 1: Cloning of the rP40 gene

The gene encoding the recombinant P40 protein, named rP40, was obtained by PCR amplification using the genomic DNA of Klebsiella *pneumoniae* IP I145 (Nguyen et al., Gene, 1998). The coding gene fragment of rP40 is inserted into various expression vectors, in particular a vector under the control of the Trp operon promoter. The amino acid sequence of the rP40 protein and the nucleotide sequence encoding the P40 protein are represented by the sequences SEQ ID No 2 and SEQ ID No 1, respectively, in the sequence listing hereinafter.

An *E. coli* K12 producer strain was transformed with an expression vector pvaLP40. The rP40 protein is

produced in the form of inclusion bodies with a significant yield (> 10%, g of proteins/g of dry biomass). This example is only an illustration of the expression of rP40, but it may be extended to other bacterial strains, and also to other expression vectors.

Example 2: Process for fermenting rP40 fusion proteins

An Erlenmeyer containing 250 ml of TSB (Tryptic Soy Broth, Difco) medium containing ampicillin (100 µg/ml, Sigma) and tetracycline (8 µg/ml, Sigma) is inoculated with the recombinant *E. coli* strain described above. The incubation is carried out overnight at 37°C, and then 200 ml of this culture is used to seed 2 liters of culture medium in a fermenter (Biolafitte, France). In a quite conventional way, the culture medium can be composed of chemical agents, supplemented with vitamins and/or yeast extracts, known to have a growth at high density of bacterial cells.

The parameters controlled during the fermentation are: the pH, the stirring, the temperature, the level of oxygenation and the supply of combined sources (glycerol or glucose). In general, the pH is regulated at 7.0 and the temperature is fixed at 37°C. The growth is controlled by supplying glycerol (87%) at a constant flow rate (12 ml/h) so as to maintain the dissolved oxygen tension signal at 30%. When the turbidity of the culture (measured at 580 nm) reaches the value of 80 (after approximately 24 hours of culturing), the protein production is triggered by adding indole acrylic acid (IAA) at the final concentration of 25 mg/l. Approximately 4 hours after induction, the cells are harvested by centrifugation. The amount of wet biomass obtained is approximately 200 g.

Example 3: Process for extracting and for purifying the rP40 protein

Extraction of rP40

After centrifugation of the culture broth (4000 rpm, 10 min, 4°C), the cells are resuspended in a 25 mM Tris-HCl buffer, pH 8.5. The insoluble substances or inclusion bodies are obtained after treatment with lysozyme (0.5 g/liter, 1 hour at room temperature / gentle stirring). The inclusion body pellet obtained by centrifugation (50 min at 10 000 g at 4°C) is taken up in a 25 mM Tris-HCl buffer at pH 8.5, containing 5 mM $MgCl_2$, and then centrifuged (15 min at 10 000 g).

The inclusion bodies are solubilized at 37°C for 2 hours in a 25 mM Tris-HCl buffer, pH 8.5, containing 7 M urea (denaturing agent) and 10 mM dithiothreitol (reduction of disulfide bridges). Centrifugation (15 min at 10 000 g) makes it possible to eliminate the insoluble particles.

Thirteen volumes of 25 mM Tris-HCl buffer, pH 8.5, containing NaCl (8.76 g/l) and Zwittergent 3-14 (0.1%, w/v) are then used to resuspend. The solution is left overnight at room temperature with gentle stirring, in contact with the air (promotes the renaturation of the protein by dilution and reoxidation of the disulfide bridges).

Purification of the rP40 protein

Anion exchange chromatography step.

After a further centrifugation, the solution is dialyzed against a 25 mM Tris-HCl buffer, pH 8.5, containing 0.1% Zwittergent 3-14 (100 X volumes of buffer) overnight at 4°C.

The dialysate is loaded onto a column containing a support of strong anion exchange type (Biorad Macro Prep High Q gel), equilibrated in the buffer described above, at a linear flow rate of 15 cm/h. The proteins are detected at 280 nm. The rP40 protein is eluted, with a linear flow rate of 60 cm/h, for a concentration of NaCl of 0.2 M in the 25 mM Tris-HCl, pH 8.5, 0.1% Zwittergent 3-14 buffer.

Cation exchange chromatography step

The fractions containing the rP40 protein are pooled and concentrated by ultrafiltration with the aid of an Amicon stirring cell system used with a Diaflo membrane of YM10 type (cut-off threshold 10 kDa), for volumes of about 100 ml, or with the aid of a millipore Minitan tangential-flow filtration system used with membrane plates having a cut-off threshold of 10 kDa, for larger volumes. The fraction thus concentrated is dialyzed overnight at 4°C against a 20 mM citrate buffer, pH 3.0, containing 0.1% of Zwittergent 3-14.

The dialysate is loaded onto a column containing a support of strong cation exchange type (Biorad Macro Prep High S gel), equilibrated in the 20 mM citrate buffer, pH 3.0, containing 0.1% of Zwittergent 3-14. The rP40 protein is eluted (rate 61 cm/h) for a concentration of NaCl of 0.7 M. The electrophoretic profiles show a degree of purity of about 95%. The condition of the protein is monitored by SDS-PAGE. The P40 protein extracted from the Klebsiella *pneumoniae* membrane has a characteristic electrophoretic behavior (migration) according to its denatured or native form. The native form (β-sheet structure) in fact has a lower molecular mass than the form denatured (α-helix structure) under the action of a denaturing agent, such as urea or guanidine hydrochloride, or with heating at 100°C in the presence of SDS. The rP40 protein is not correctly renatured at the end of renaturation, whether this renaturation is carried out in the presence or absence of 0.1% (w/v) Zwittergent 3-14. On the other hand, total renaturation is obtained after dialysis against a 25 mM Tris/HCl buffer, pH 8.5, containing 0.1% (w/v) of Zwittergent 3-14. However, it should be noted that this renaturation is obtained only when the dilution step and the treatment at room temperature are, themselves, carried out in the presence of Zwittergent 3-14 (negative results in the absence of detergent).

Example 4: Specific binding of rP40 to antigen-presenting cells (APCs). Methodology

Purification of human T lymphocytes

Mononucleated cells (MNCs) are isolated from the peripheral blood of healthy volunteers, by centrifugation (1800 rpm, 20 min, room temperature), on a Ficoll gradient. After centrifugation, the MNCs, located at the ficoll/plasma interface, are harvested and washed twice with complete culture medium (CM) (RPMI 1640 + 10% FCS + L-glutamine + antibiotic). The T lymphocytes are then isolated by the rosetting technique, which uses their capacity to bind to sheep red blood cells (SRBCs). Briefly, the MNCs are incubated with SRBCs for 1 hour at 4°C. After centrifugation on a ficoll gradient, the B lymphocytes and monocytes are located at the interface, whereas the T lymphocytes bound to the SRBCs are in the cell pellet. After recovery of the cell pellet and lysis of the SRBCs with a hypotonic saline solution, the purity of the T lymphocytes is assessed by flow cytometry with an anti-CD3 antibody, and is greater than 95%.

Purification of the human monocytes

The monocytes are purified from the MNCs by positive selection using MACS (Magnetic Activated Cell Sorter) technology. The MNCs are labeled with an anti-CD14 antibody coupled to magnetic particles, and then passed over a magnetized column. The monocytes to which the antibody-colloid complexes are bound remain in the column, whereas the cells which have not bound the antibody are eluted with successive washes. Next, the monocytes are detached by performing washes in the absence of magnet. The purity of the fraction collected is greater than 98%.

Generation of human dendritic cells (DCs) from monocytes

The purified monocytes are cultured at the concentration of 106/ml in CM for 6 to 7 days, in the presence of IL 4 (20 ng/ml) and of CMCSF (20 ng/ml). The DCs generated at this stage are immature DCs which

express CDIa and no, or relatively little, CD83. Their phenotype is verified using the flow cytometry technique.

Purification of human B lymphocytes from tonsils

The tonsils are ground, and the cells harvested are loaded onto a ficoll gradient. The MNCs recovered at the interface are washed and then incubated with SRBCs. After ficoll, the B lymphocytes are located at the interface, whereas the T lymphocytes bound to the SRBCs are in the cell pellet. The B lymphocytes are then washed. Their purity, verified by flow cytometry, is greater than 96%.

Culturing of cell lines

The RPMI 8866, DAUDI, HL60 and Jurkat cell lines are cultured in CM.

Coupling of rP40 to the Alexa488 fluorochrome

The concentration of the rP40 protein is adjusted to 2 mg/ml in PBS. 50 µl of 1 M sodium bicarbonate are added to 500 µl of the protein. The solution is then transferred into a reaction tube containing the Alexa488 dye and the coupling takes place at room temperature. After 1 h, the coupling reaction is stopped by adding 15 µl of hydroxylamine. The labeled protein is separated from the free dye by column purification.

The amount of rP40 labeled with Alexa488 is then estimated by colorimetric assay.

- Study of the binding of p40-Alexa488 to the various cells, by flow cytometry.

For each labeling, 200 000 cells are washed with FACS buffer (PBS + 1% BSA + 0.01% sodium azide) and resuspended, in a cone-bottomed 96-well plate, in 50 µl of FACS buffer. The P40-Alexa488 protein or the control protein (glycophorin-Alexa488) are then added at 10^{-6}M for approximately 1 h at 4°C. After incubation, the cells are then washed 3 times with FACS buffer, and then resuspended in 200 µl of this same buffer and analyzed by flow cytometry.

Result

The rP40 protein binds selectively to human APCs such as:

- the monocytes derived from human blood,
- the dendritic cells generated from the peripheral blood monocytes,
- the B lymphocytes derived from tonsils, the B-lymphocyte lines: DAUDI and RPMI 8866 (cf. fig. 1) and the B lymphocytes derived from peripheral blood (result not shown).

No binding is observed to cells which do not have the capacity to present antigens, such as nonactivated peripheral blood T lymphocytes, the nonactivated Jurkat T-lymphocyte line and the nonactivated HL60 monocyte line.

Example 5: The binding of rP40 to the DCs is specific

1) The binding of rP40 to the DCs is dose-dependent.

Method

200 000 DCs are washed with FACS buffer and incubated in 50 µl of buffer in the presence of various concentrations of rP40 (from 10^{-10} to 5 x 10^{-6} M) for approximately 1 hour at 4°C. After incubation, the cells are washed 3 times with FACS buffer, and then resuspended in 50 µl of this same buffer containing 5 µg/ml of an anti-P40 rabbit polyclonal antibody or of a control rabbit IgG antibody. After incubation for 20 minutes, the cells are rewashed and incubated in 100 µl of FACS buffer containing a floresceine-labeled anti-rabbit IgG goat polyclonal antibody (diluted to 1:200). After incubation for 20 minutes, the cells are washed, taken up in FACS buffer and analyzed by flow cytometry.

Result

The binding of rP40 to the DC is significant from 10^{-7} M ($p<0.001$) and at a maximum at 2 x 10^{-6} M (cf. fig. 2).

2) Unlabeled rP40 protein decreases the binding of rP40 Alexa488 to the DCs.

Method

In order to demonstrate the specificity of the binding of P40, competition is carried out between rP40-Alexa488 and unlabeled rP40. The DCs were incubated for 10 minutes with 5×10^{-8} to 2×10^{-6} M of unlabeled rP40, and then P40-Alexa488 (used at 2×10^{-6} M) was added. After incubation for 20 minutes at 4°C, the cells were analyzed by flow cytometry as described previously.

Result

The unlabeled rP40 protein inhibits, in a dose-dependent manner, the binding of 2×10^{-6} M of P40 Alexa488 (at more than 60% when it is used at 2×10^{-6} M) (cf. fig. 3).

Example 6: Among the TT, BB and rP40 carrier proteins, only the rP40 protein binds to the DCs.

Method

The tetanus anatoxin (TT) and BB (originating from the streptococcus G protein having affinity for human albumin) carrier proteins, and also the rP40 protein and the glycophorin A control protein were labeled with Alexa488 as described above. The binding of these molecules to the DCs was evaluated by flow cytometry as previously described. Briefly, 200 000 DCs are washed with FACS buffer and incubated in 50 µl of buffer in the presence of 10^{-6} M of each of the Alexa488-labeled proteins for approximately 1 hour at 4°C. After incubation, the cells are washed 3 times with FACS buffer, and then resuspended in 200 µl of this same buffer and analyzed by flow cytometry.

Result

At the concentration of 10^{-6} M, only rP40 binds to the dendritic cells. No binding of TT, BB and glycophorin is detected (cf. fig. 4).

Example 7: rP40 is internalized by the DCs

Method

200 000 DCs are washed with PBS-1% BSA buffer and resuspended, in a cone-bottomed 96-well plate, in 50 µl of PBS-BSA buffer (saline phosphate-bovine serum albumin buffer). The rP40-Alexa488 protein or the glycophorin-Alexa488 protein is then added at 2×10^{-6} M. Internalization kinetics are produced by incubating the cells with the Alexa-labeled proteins at 37°C for 15 minutes to 2 hours. A negative control for internalization is carried out under the same conditions, changing the following parameters: addition of 0.01% sodium azide to the PBS-BSA buffer and incubation of these cells with the Alexa-labeled proteins, at 4°C.

After incubation, the cells are then washed 3 times with PBS-BSA buffer, resuspended in 100 µl of this same buffer and then cytospun onto microscope slides. The slides are then analyzed by confocal microscopy.

Result

The observation of the cells incubated at 37°C with rP40-Alexa shows intracytoplasmic labeling which is detectable from 30 minutes and still observed after incubation for 2 h: a representative result, obtained after incubation for 1 h at 37°C is shown in figure 5B. Labeling of the membrane, but not intracytoplasmic labeling, is observed when the cells are incubated at 4°C with rP40 (cf. fig. 5A), whereas no labeling is observed in the presence of glycophorin-Alexa (after incubation at 4°C as at 37°C). The example of Alexa, a chemical molecule, demonstrates that any chemical molecule coupled to P40 can thus be delivered to antigen-presenting cells, including dendritic cells.

CLAIMS

1. The use of an enterobacterium OmpA protein, or of a fragment thereof, for preparing a pharmaceutical composition intended for specific targeting of a biologically active substance which is associated with it to antigen-presenting cells, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is internalized into the antigen-presenting cells.

2. The use as claimed in claim 1, characterized in that said enterobacterium OmpA protein, or a fragment thereof, binds specifically to antigen-presenting cells.

3. The use as claimed in either of claims 1 and 2, characterized in that said antigen-presenting cells are chosen from dendritic cells, monocytes and B lymphocytes.

4. The use as claimed in claim 3, characterized in that said antigen-presenting cells are dendritic cells.

5. The use as claimed in one of claims 1 to 4, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained from a culture of said enterobacterium, using an extraction process.

6. The use as claimed in one of claims 1 to 4, characterized in that said enterobacterium OmpA protein, or a fragment thereof, is obtained by recombinant process.

7. The use as claimed in one of claims 1 to 6, characterized in that said enterobacterium is Klebsiella *pneumoniae*.

8. The use as claimed in claim 7, characterized in that the amino acid sequence of said OmpA protein, or a fragment thereof, comprises:

a) the amino acid sequence having sequence SEQ ID No 2;

b) the amino acid sequence of a sequence having at least 80% homology with the sequence SEQ ID No 2; or

c) the amino acid sequence of a fragment, of at least 5 amino acids, of a sequence as defined in a) or b).

9. The use as claimed in one of claims 1 to 8, characterized in that said biologically active substance is chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids and chemical substances.

10. The use as claimed in claim 9, characterized in that said biologically active substance is coupled by covalent attachment with said OmpA protein, or a fragment thereof.

11. The use as claimed in claim 10, characterized in that the coupling by covalent attachment is chemical coupling.

12. The use as claimed in claim 11, characterized in that one or more attachment elements is (are) introduced into said OmpA protein, or a fragment thereof, and/or into said biologically active substance, in order to facilitate the chemical coupling.

13. The use as claimed in claim 12, characterized in that said attachment element introduced is an amino acid.

14. The use as claimed in claim 10, characterized in that said biologically active substance coupled by covalent attachment with said OmpA protein, or a fragment thereof, is a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

15. The use as claimed in one of claims 10 to 14, characterized in that said biologically active substance is an antigen or a hapten.

SUBSTITUTE SHEET (RULE 26)

16. The use as claimed in one of claims 1 to 15, for modifying the immune response against an antigen or a hapten.

17. The use as claimed in claim 16, for improving the immune response against an antigen or a hapten.

18. The use as claimed in one of claims 1 to 17, for preparing a pharmaceutical composition intended to prevent or to treat a disease with an active substance the effectiveness of which is modified by and/or linked to the internalization thereof by antigen-presenting cells.

19. The use as claimed in claim 18, for preparing a pharmaceutical composition intended to prevent or to treat a disease with an active substance, the effectiveness of which is modified by and/or linked to the internalization thereof by dendritic cells.

20. The use as claimed in either of claims 18 and 19, for preparing a pharmaceutical composition intended to prevent or to treat cancers, preferably cancers associated with a tumor antigen, autoimmune diseases, allergies, graft rejections, cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, infectious diseases or diseases linked to an immunodeficiency.

21. The use as claimed in claim 20, for preparing a pharmaceutical vaccine composition intended to prevent or to treat an infectious disease or a cancer associated with a tumor antigen.

22. The use as claimed in one of claims 18 to 21, characterized in that said pharmaceutical composition also comprises an adjuvant of immunity.

23. The use as claimed in one of claims 18 to 22, characterized in that said pharmaceutical composition is vehicled in a form which makes it possible to improve the stability and/or immunogenicity thereof.

24. The use as claimed in claim 23, characterized in that said pharmaceutical composition is vehicled in the form of a liposome, of a viral vector or of a

EPO - DG 1 25. 09. 2000 (09)

transformed host cell capable of expressing a recombinant chimeric protein resulting from the expression of a nucleic acid construct encoding said biologically active substance and said OmpA protein, or a fragment thereof.

PCT/EP00/09273

PCT ORGANISATION MONDIALE DE LA PROPRIETE INTELLECTUELLE
Bureau international

DEMANDE INTERNATIONALE PUBLIEE EN VERTU DU TRAITE DE COOPERATION EN MATIERE DE BREVETS (PCT)

(51) **Classification internationale des brevets** [7] : **A61K 39/385, 39/39, A61P 31/00, 35/00, 37/00** | **A1**

(11) **Numéro de publication internationale:** **WO 00/27432**

(43) **Date de publication internationale:** 18 mai 2000 (18.05.00)

(21) **Numéro de la demande internationale:** PCT/FR99/02734

(22) **Date de dépôt international:** 8 novembre 1999 (08.11.99)

(30) **Données relatives à la priorité:**
98/14007 6 novembre 1998 (06.11.98) FR

(71) **Déposant** *(pour tous les Etats désignés sauf US)*: PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel Gance, F–92100 Boulogne–Billancourt (FR).

(72) **Inventeurs; et**
(75) **Inventeurs/Déposants** *(US seulement)*: BONNEFOY, Jean–Yves [FR/FR]; Les Noyers, F–74350 Le Sappey (FR). LECOANET, Sybille [CH/CH]; 41, A1 Résidence du Golf, CH–1196 Gland (CH). AUBRY, Jean–Pierre [FR/FR]; 60, chemin des Crêts des Crêts, F–74350 Cuvat (FR). JEANNIN, Pascale [FR/FR]; 135, chemin de Révule, F–01220 Divonne–les–Bains (FR). BAUSSANT, Thierry [FR/FR]; 35, rue Jean Jaurès, F–01200 Bellegarde (FR).

(74) **Mandataires:** MARTIN, Jean–Jacques etc.; Cabinet Regimbeau, 26, avenue Kléber, F–75116 Paris (FR).

(81) **Etats désignés:** AU, BR, CA, CN, JP, MX, US, ZA, brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Publiée
Avec rapport de recherche internationale.
Avant l'expiration du délai prévu pour la modification des revendications, sera republiée si des modifications sont reçues.

(54) **Title:** USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN–PRESENTING CELLS

(54) **Titre:** UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE VERS LES CELLULES PRESENTATRICES D'ANTIGENES

(57) **Abstract**

The invention concerns the use of an enterobacterium protein OmpA, preferably Klebsiella *pneumoniae* P40 protein, for specific targeting of a biologically active substance associated therewith towards antigen–presenting cells, in particular human dendritic cells. The invention also concerns the use of the OmpA protein for preparing a pharmaceutical composition for preventing and/or treating diseases, in particular cancers related to a tumour–associated antigen, autoimmune diseases or infectious diseases.

(57) **Abrégé**

L'invention concerne l'utilisation d'une protéine OmpA d'entérobactérie, de préférence la protéine P40 klebsiella *pneumoniae*, pour le ciblage spécifique d'une substance biologiquement active qui lui est associée vers les cellules présentatrices d'antigènes, notamment les cellules dendritiques humaines. L'invention a également pour objet l'utilisation de la protéine OmpA pour la préparation d'une composition pharmaceutique destinée à la prévention et/ou le traitement de maladies, notamment les cancers associés à un antigène tumoral, les maladies auto–immunes ou les maladies infectieuses.


Dendritic cells
Glycophorine-Alexa
P40-Alexa
Monocytes
T lymphocytes
B lymphocytes
RPMI 8866
Daudi
HL60
Jurkat
number of cells
Fluorescence (log)

FIGURE 1



FIGURE 2



FIGURE 3


TT-Alexa
BB-Alexa
P40-Alexa
Glycophorin-Alexa
number of cells
Fluorescence (log)

FIGURE 4



FIGURE 5A



FIGURE 5B

09/831061
JC18 Rec'd PCT/PTO 04 MAY 2001

SEQUENCE LISTING

<110> PIERRE FABRE MÉDICAMENT

<120> USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR SPECIFIC TARGETING OF A BIOLOGICALLY ACTIVE SUBSTANCE WHICH IS ASSOCIATED WITH IT TO ANTIGEN-PRESENTING CELLS

<130> D17777

<140>
<141>

<150> FR 98 14007
<151> 1998-11-06

<160> 2

<170> PatentIn Ver. 2.2

<210> 1
<211> 1035
<212> ADN
<213> Klebsiella pneumoniae

<220>
<221> exon
<222> (1)..(1032)

<220>
<221> intron
<222> (1033)..(1035)

<220>
<221> CDS
<222> (1)..(1032)

<400> 1

```
atg aaa gca att ttc gta ctg aat gcg gct ccg aaa gat aac acc tgg   48
Met Lys Ala Ile Phe Val Leu Asn Ala Ala Pro Lys Asp Asn Thr Trp
  1               5                  10                  15

tat gca ggt ggt aaa ctg ggt tgg tcc cag tat cac gac acc ggt ttc   96
Tyr Ala Gly Gly Lys Leu Gly Trp Ser Gln Tyr His Asp Thr Gly Phe
            20                  25                  30

tac ggt aac ggt ttc cag aac aac aac ggt ccg acc cgt aac gat cag   144
Tyr Gly Asn Gly Phe Gln Asn Asn Asn Gly Pro Thr Arg Asn Asp Gln
        35                  40                  45

ctt ggt gct ggt gcg ttc ggt ggt tac cag gtt aac ccg tac ctc ggt   192
Leu Gly Ala Gly Ala Phe Gly Gly Tyr Gln Val Asn Pro Tyr Leu Gly
    50                  55                  60

ttc gaa atg ggt tat gac tgg ctg ggc cgt atg gca tat aaa ggc agc   240
Phe Glu Met Gly Tyr Asp Trp Leu Gly Arg Met Ala Tyr Lys Gly Ser
65                  70                  75                  80

gtt gac aac ggt gct ttc aaa gct cag ggc gtt cag ctg acc gct aaa   288
Val Asp Asn Gly Ala Phe Lys Ala Gln Gly Val Gln Leu Thr Ala Lys
```

```
                85                  90                  95

ctg ggt tac ccg atc act gac gat ctg gac atc tac acc cgt ctg ggc   336
Leu Gly Tyr Pro Ile Thr Asp Asp Leu Asp Ile Tyr Thr Arg Leu Gly
            100                 105                 110

ggc atg gtt tgg cgc gct gac tcc aaa ggc aac tac gct tct acc ggc   384
Gly Met Val Trp Arg Ala Asp Ser Lys Gly Asn Tyr Ala Ser Thr Gly
        115                 120                 125

gtt tcc cgt agc gaa cac gac act ggc gtt tcc cca gta ttt gct ggc   432
Val Ser Arg Ser Glu His Asp Thr Gly Val Ser Pro Val Phe Ala Gly
    130                 135                 140

ggc gta gag tgg gct gtt act cgt gac atc gct acc cgt ctg gaa tac   480
Gly Val Glu Trp Ala Val Thr Arg Asp Ile Ala Thr Arg Leu Glu Tyr
145                 150                 155                 160

cag tgg gtt aac aac atc ggc gac gcg ggc act gtg ggt acc cgt cct   528
Gln Trp Val Asn Asn Ile Gly Asp Ala Gly Thr Val Gly Thr Arg Pro
                165                 170                 175

gat aac ggc atg ctg agc ctg ggc gtt tcc tac cgc ttc ggt cag gaa   576
Asp Asn Gly Met Leu Ser Leu Gly Val Ser Tyr Arg Phe Gly Gln Glu
            180                 185                 190

gat gct gca ccg gtt gtt gct ccg gct ccg gct ccg gct ccg gaa gtg   624
Asp Ala Ala Pro Val Val Ala Pro Ala Pro Ala Pro Ala Pro Glu Val
        195                 200                 205

gct acc aag cac ttc acc ctg aag tct gac gtt ctg ttc aac ttc aac   672
Ala Thr Lys His Phe Thr Leu Lys Ser Asp Val Leu Phe Asn Phe Asn
    210                 215                 220

aaa gct acc ctg aaa ccg gaa ggt cag cag gct ctg gat cag ctg tac   720
Lys Ala Thr Leu Lys Pro Glu Gly Gln Gln Ala Leu Asp Gln Leu Tyr
225                 230                 235                 240

act cag ctg agc aac atg gat ccg aaa gac ggt tcc gct gtt gtt ctg   768
Thr Gln Leu Ser Asn Met Asp Pro Lys Asp Gly Ser Ala Val Val Leu
                245                 250                 255

ggc tac acc gac cgc atc ggt tcc gaa gct tac aac cag cag ctg tct   816
Gly Tyr Thr Asp Arg Ile Gly Ser Glu Ala Tyr Asn Gln Gln Leu Ser
            260                 265                 270

gag aaa cgt gct cag tcc gtt gtt gac tac ctg gtt gct aaa ggc atc   864
Glu Lys Arg Ala Gln Ser Val Val Asp Tyr Leu Val Ala Lys Gly Ile
        275                 280                 285

ccg gct ggc aaa atc tcc gct cgc ggc atg ggt gaa tcc aac ccg gtt   912
Pro Ala Gly Lys Ile Ser Ala Arg Gly Met Gly Glu Ser Asn Pro Val
    290                 295                 300

act ggc aac acc tgt gac aac gtg aaa gct cgc gct gcc ctg atc gat   960
Thr Gly Asn Thr Cys Asp Asn Val Lys Ala Arg Ala Ala Leu Ile Asp
305                 310                 315                 320

tgc ctg gct ccg gat cgt cgt gta gag atc gaa gtt aaa ggc tac aaa   1008
Cys Leu Ala Pro Asp Arg Arg Val Glu Ile Glu Val Lys Gly Tyr Lys
                325                 330                 335
```

gaa gtt gta act cag ccg gcg ggt taa 1035
Glu Val Val Thr Gln Pro Ala Gly
340

<210> 2
<211> 344
<212> PRT
<213> Klebsiella pneumoniae

<400> 2
Met Lys Ala Ile Phe Val Leu Asn Ala Ala Pro Lys Asp Asn Thr Trp
1 5 10 15

Tyr Ala Gly Gly Lys Leu Gly Trp Ser Gln Tyr His Asp Thr Gly Phe
20 25 30

Tyr Gly Asn Gly Phe Gln Asn Asn Asn Gly Pro Thr Arg Asn Asp Gln
35 40 45

Leu Gly Ala Gly Ala Phe Gly Gly Tyr Gln Val Asn Pro Tyr Leu Gly
50 55 60

Phe Glu Met Gly Tyr Asp Trp Leu Gly Arg Met Ala Tyr Lys Gly Ser
65 70 75 80

Val Asp Asn Gly Ala Phe Lys Ala Gln Gly Val Gln Leu Thr Ala Lys
85 90 95

Leu Gly Tyr Pro Ile Thr Asp Asp Leu Asp Ile Tyr Thr Arg Leu Gly
100 105 110

Gly Met Val Trp Arg Ala Asp Ser Lys Gly Asn Tyr Ala Ser Thr Gly
115 120 125

Val Ser Arg Ser Glu His Asp Thr Gly Val Ser Pro Val Phe Ala Gly
130 135 140

Gly Val Glu Trp Ala Val Thr Arg Asp Ile Ala Thr Arg Leu Glu Tyr
145 150 155 160

Gln Trp Val Asn Asn Ile Gly Asp Ala Gly Thr Val Gly Thr Arg Pro
165 170 175

Asp Asn Gly Met Leu Ser Leu Gly Val Ser Tyr Arg Phe Gly Gln Glu
180 185 190

Asp Ala Ala Pro Val Val Ala Pro Ala Pro Ala Pro Ala Pro Glu Val
195 200 205

Ala Thr Lys His Phe Thr Leu Lys Ser Asp Val Leu Phe Asn Phe Asn
210 215 220

Lys Ala Thr Leu Lys Pro Glu Gly Gln Gln Ala Leu Asp Gln Leu Tyr
225 230 235 240

Thr Gln Leu Ser Asn Met Asp Pro Lys Asp Gly Ser Ala Val Val Leu
245 250 255

Gly Tyr Thr Asp Arg Ile Gly Ser Glu Ala Tyr Asn Gln Gln Leu Ser

```
            260                 265                 270

Glu Lys Arg Ala Gln Ser Val Val Asp Tyr Leu Val Ala Lys Gly Ile
        275                 280                 285

Pro Ala Gly Lys Ile Ser Ala Arg Gly Met Gly Glu Ser Asn Pro Val
    290                 295                 300

Thr Gly Asn Thr Cys Asp Asn Val Lys Ala Arg Ala Ala Leu Ile Asp
305                 310                 315                 320

Cys Leu Ala Pro Asp Arg Arg Val Glu Ile Glu Val Lys Gly Tyr Lys
                325                 330                 335

Glu Val Val Thr Gln Pro Ala Gly
            340
```

SUBSTITUTE SHEET (RULE 26)

OIPE
AUG 31 2001
PATENT & TRADEMARK OFFICE

PF86PCTSEQ
ATTY DK No. _____

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled. **USE OF AN ENTEROBACTERIUM OmpA PROTEIN FOR SPECIFIC TARGETING TO ANTIGEN-PRESENTING CELLS**,

the specification of which (check one of the following)

☐ is attached hereto; ☐ was filed on _____ as Application Serial No. _____ and was amended on _____; (if applicable)

☒ was filed as PCT International Application No. **PCT/FR99/02734** on **08 NOVEMBER 1999** and was amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
98 14007 (Number)	FRANCE (Country)	06/11/98 (Day/Month/Year Filed)	☒ Yes	☐ No
(Number)	(Country)	(Day/Month/Year Filed)	☐ Yes	☐ No
(Number)	(Country)	(Day/Month/Year Filed)	☐ Yes	☐ No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

PCT/FR99/02734	08 NOVEMBER 1999	pending
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

G.Patrick Sage Reg. No. 37,710

Send Correspondence to:

G. Patrick Sage
THE FIRM OF HUESCHEN AND SAGE
500 Columbia Plaza
350 East Michigan Avenue
Kalamazoo, Michigan 49007-3856
United States of America

Direct Telephone Calls to: (name and telephone number) **616-382-0030**

FULL NAME OF SOLE OR FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE
BONNEFOY Jean-Yves		May 9, 2001
RESIDENCE: LE SAPPEY - FRANCE FRX		CITIZENSHIP: FRANCE
POST OFFICE ADDRESS: Les Noyers - 74350 LE SAPPEY - FRANCE		

FULL NAME OF SECOND JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
LECOANET Sybille	S. Lecoanet	May 9, 2001
RESIDENCE: GLAND - SWITZERLAND CHX		CITIZENSHIP: SWITZERLAND
POST OFFICE ADDRESS: 41, A1 Résidence du Golf - 1196 GLAND - SWITZERLAND		

FULL NAME OF THIRD JOINT INVENTOR, IF ANY	INVENTOR'S SIGNATURE	DATE
AUBRY Jean-Pierre		May 9, 2001
RESIDENCE: CUVAT - FRANCE FRX		CITIZENSHIP: FRANCE
POST OFFICE ADDRESS: 60 Chemin des Crêts des Crêts - 74350 CUVAT - FRANCE		

Listing of Inventors Continued on Page 3 hereof. ☒ Yes ☐ No

4.00

Full Name of Fourth Joint Inventor, if any: JEANNIN Pascale
Inventor's Signature
Date: May 9, 2001

Residence: DIVONNE-LES-BAINS - FRANCE FRX
Citizenship: FRANCE

Post Office Address: 135 Chemin de Révule - 01220 DIVONNE-LES-BAINS - FRANCE

5.00 TB

Full Name of Fifth Joint Inventor, if any: BAUSSANT Thierry
Inventor's Signature
Date: May 9, 2001

Residence: **new address: 4 rue Alphonse Baudin, ~~01200~~ ~~BELLEGARDE,~~ FRANCE**
BELLEGARDE - FRANCE FRX
Citizenship: FRANCE

TB

Post Office Address: **new address: 4 rue Alphonse Baudin, 01200 BELLEGARDE, FRANCE**
~~35 Rue Jean Jaurès - 01200 BELLEGARDE - FRANCE~~

Full Name of Sixth Joint Inventor, if any
Inventor's Signature
Date

Residence
Citizenship

Post Office Address